After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Akero Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Akero Therapeutics Inc is $1.75B. A total of 0.88 million shares were traded on the day, compared to an average of 691.22K shares.
In the most recent transaction, Young Jonathan sold 10,000 shares of AKRO for 28.03 per share on Jan 02 ’25. After the transaction, the Chief Operating Officer now owns 218,083 company shares. In a previous transaction on Jan 02 ’25, Jonathan Young bought 70,000 shares at 27.82 per share.
Among the insiders who sold shares, Lamy Patrick disposed of 1,000 shares on Dec 16 ’24 at a per-share price of $29.13. This resulted in the Senior VP, Commercial Strategy holding 34,258 shares of AKRO after the transaction. In another insider transaction, Yale Catriona sold 9,074 shares at $29.11 per share on Dec 16 ’24. Company shares held by the Chief Development Officer now total 95,648.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, AKRO has a high of $37.00 and a low of $15.32.
As of this writing, AKRO has an earnings estimate of -$1.14 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$1.07 per share and a lower estimate of -$1.19.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $10.61, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 4.83.
